The annual accounting of national health spending is out. And the 2018 health bill for the U.S. was $3.6 trillion, consuming nearly a fifth of the nation’s economy. Meanwhile, Congress is nearing the end of the year without having finished either its annual spending bills or several other high-priority health items. Kimberly Leonard of the Washington Examiner, Joanne Kenen of Politico and Mary Agnes Carey of Kaiser Health News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk about the latest KHN-NPR “Bill of the Month.”
Open enrollment for the Affordable Care Act’s marketplace plans is halfway over and, so far, the number of people signing up is down, but not dramatically. Meanwhile, Congress and President Donald Trump can’t seem to agree on what to do about teen vaping, drug prices or “surprise” medical bills. And Democrats lurch to the left on abortion. Paige Winfield Cunningham of The Washington Post, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news.
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.”
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.